Professor and Chief of Vascular Surgery
University Medical Center Rotterdam
Professor
Erasmus University Medical Center Rotterdam
Rotterdam, The Netherlands
Presenter
SESSION 6: MORE ABOUT AAAS AND EVAR, STANDARD AND COMPLEX: UPDATES ON PHYSICIAN MODIFIED ENDOGRAFTS (PMEGS) AND GUIDELINES
Presenter
SESSION 8: MORE NEW DEVELOPMENTS REGARDING TBADS AND TEVAR: NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TYPE B AORTIC DISSECTION (UTBADS)
Presenter
SESSION 33: A) PROGRESS IN MANAGING ENDOLEAKS: UNDERSTANDING THEIR CONSEQUENCES AND PREDICTING, PREVENTING AND TREATING THEM; B) DR. CYNAMON'S GAME CHANGING INNOVATIONS
Presenter
SESSION 44: MORE NEW DEVELOPMENTS IN AAAS: ENDOVASCULAR TREATMENTS WITH HERITABLE AORTIC DISEASE (CONNECTIVE TISSUE GENETIC DISORDERS - CTDS): HOW DOES INTRASAC THROMBUS LOAD AFFECT AAA BEHAVIOR AND PROGNOSIS AFTER EVAR
Presenter
SESSION 56: NEW OR UPDATED EVAR DEVICES FOR AAAS, COMPLEX AAAS, TAAAS OR ARCH TEVARS
SESSION 6: MORE ABOUT AAAS AND EVAR, STANDARD AND COMPLEX: UPDATES ON PHYSICIAN MODIFIED ENDOGRAFTS (PMEGS) AND GUIDELINES
What Are The New ESVS Guidelines For Surveillance After EVAR And Do They Lead To Unsafe Practices
3:16 PM - 3:21 PM
Presenter
SESSION 8: MORE NEW DEVELOPMENTS REGARDING TBADS AND TEVAR: NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TYPE B AORTIC DISSECTION (UTBADS)
The Science Behind The High Risk Features Of Uncomplicated Acute Type B Dissections (uTBADs) Is Shaky At Best: They Should Not Be Used As An Excuse To Treat These Patients Invasively (As Some Guidelines Suggest) Until We Have Better Evidence: Until Then An RCT Will Be Difficult Or Impossible
5:26 PM - 5:31 PM
Presenter
SESSION 33: A) PROGRESS IN MANAGING ENDOLEAKS: UNDERSTANDING THEIR CONSEQUENCES AND PREDICTING, PREVENTING AND TREATING THEM; B) DR. CYNAMON'S GAME CHANGING INNOVATIONS
Most Type 2 Endoleaks After EVAR Should Be Left Alone Because Treatments Have Poor Results, Have Complications And Do Not Improve Outcomes: What Are The Exceptions
9:36 AM - 9:41 AM
Presenter
SESSION 44: MORE NEW DEVELOPMENTS IN AAAS: ENDOVASCULAR TREATMENTS WITH HERITABLE AORTIC DISEASE (CONNECTIVE TISSUE GENETIC DISORDERS - CTDS): HOW DOES INTRASAC THROMBUS LOAD AFFECT AAA BEHAVIOR AND PROGNOSIS AFTER EVAR
DEBATE: Large Flow Luminal Space In An AAA Sac With Minimal Mural Thrombus Is Associated With Adverse Events After EVAR: It Is More Important Than AAA Sac Size: Thrombus May Be Protective
3:00 PM - 3:05 PM
Presenter
SESSION 56: NEW OR UPDATED EVAR DEVICES FOR AAAS, COMPLEX AAAS, TAAAS OR ARCH TEVARS
New Insights From The 10-Year Results Of The ENGAGE EVAR Registry: What Does It Tell Us About EVAR Durability
8:54 AM - 8:59 AM